|
Session 108
Poster Abstracts
Interpretation of Drug Resistance Tests
Tuesday, 1:30 - 3:30 pm
Poster Hall |
| 650 |
Incremental and Continuous Phenotypic Drug Susceptibility Scores more Accurately Predict Virologic and Immunologic Treatment Outcomes in HIV+ Patients Starting Salvage Therapy: Findings from the Argenta Trial
Andrea De Luca*1, J Weidler2, S Di Giambenedetto1, E Coakley2, A Bacarelli1, M Bates2, Y Lie2, R Pesano2, R Cauda1, and J Schapiro3
1Catholic Univ, Rome, Italy; 2Monogram Biosci, South San Francisco, CA, US; and 3Sheba Med Ctr, Tel Hashomer, Israel |
| 651 |
Antiretroviral Phenotypic Susceptibility Score as a Predictor of Treatment Response in Persons with Multi-drug-resistant HIV-1
Jody Lawrence*1, K Huppler Hullsiek2, E Coakley3, M Bates3, J Weidler3, Y Lie3, R Pesano3, L Thackeray2, J Baxter4, and the 064 Study Team of the Terry Beirn Community Prgms for Clin Res on AIDS
1Univ of California, San Francisco, US; 2Univ of Minnesota, Minneapolis, US; 3Monogram Biosci, South San Francisco, CA, US; and 4Cooper Hosp, Robert Wood Johnson Med Sch, Camden, NJ, US |
652
 |
Analyzing Complex Resistance Patterns of Protease Inhibitors with Bio-informatics Resistance Determination, a Novel Approach Employing Synthetic Viral Genes Carrying Clinically Relevant Patterns of PI-resistance Mutations
Herwig Van Marck*1, G Meersseman1, I Dierynck1, L Borozdina2, G Kraus1, M P De Béthune1, S Hallenberger1, and K Hertogs1
1Tibotec, Mechelen, Belgium and 2Centocor / EGEA, San Diego, CA, US |
653
|
Neural Networks Are More Accurate Predictors of Virologic Response to ART yhan Rules-based Genotype Interpretation Systems
Brendan Larder*1, A Geretti2, L Monno3, C Torti4, A Revell1, D Wang1, R Harrigan5, J Montaner5, and H Lane6
1HIV Resistance Response Database Initiative, London, UK; 2Royal Free Hosp Cohort, London, UK; 3Univ of Bari, Italy; 4Univ of Brescia, Italy; 5BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada; and 6NIAID, NIH, DHHS, Bethesda, MD, US |
654
|
Enhanced Survival Associated with Use of HIV Susceptibility Testing among HAART-experienced Patients in the HIV Outpatient Study (HOPS)
Frank Palella*1, C Armon2, J Chmiel1, K Buchacz2, R Novak3, A Moorman2, J Brooks2, and the HOPS Investigators
1Northwestern Univ, Feinberg Sch of Med, Chicago, IL, US; 2CDC, Atlanta, GA, US; and 3Univ of Illinois Coll of Med, Chicago, US |
|
